Randox Laboratories has announced a new partnership with technology firm Bosch, with the goal of making fast and highly precise diagnostics accessible at the point of care. The two companies will invest around €150 million in joint research, development, and sales activities for new tests for the Vivalytic analysis platform provided by Bosch Healthcare.
One goal is the development of a sepsis IVD grade test that will be the first to feature innovative BioMEMS technology. The latter enables fully automatic testing of up to 250 genetic characteristics (such as pathogens) in one cartridge, in less than 15 minutes.
With its Vivalytic analysis platform, Bosch aims to achieve a leading position in the point-of-care molecular diagnostics market. Bosch Healthcare Solutions is joining forces with Randox to accelerate the development and market launch of new tests and to make distribution channels more efficient. The partnership is set to run for more than ten years.
“Globally, healthcare is moving toward decentralised and personalised diagnostics, that enable rapid interventions and individual treatment plans,” said Marc Meier, managing director of Bosch Healthcare Solutions GmbH. “With our partner Randox, we want to further expand the test portfolio of our Vivalytic analysis device. Our fully automated molecular-diagnostic PCR tests provide clarity directly at the site of sample collection, shorten waiting times, and take the strain off the healthcare system,” Meier added.
Bosch Healthcare Solutions and Randox already collaborated during the COVID-19 pandemic. In spring 2020, Bosch launched one of the world’s first fully automated PCR tests for the SARS-CoV-2 coronavirus. Together with Randox, the rapid test for use in doctor’s offices, nursing homes, testing stations, and hospitals was made ready for the Vivalytic analysis device within the space of just a few weeks.
